BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

December 22, 2016
Niels Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the company's pipeline candidates, upcoming development targets, and long-term goals. InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement system and has made breakthrough discoveries in anti-C5a antibody generation, resulting in a new class of antibodies. The company's anti-complement technology is the basis for a pipeline of new antibodies addressing a broad variety of inflammatory diseases – its lead product is currently in Phase II in patients undergoing complex cardiac surgery.
Previous Video
Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas
Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candi...

Next Video
BIO-Europe® 2016: Opportunities For unpartnered assets
BIO-Europe® 2016: Opportunities For unpartnered assets

Steven Muntner, vice president of deals at Informa Pharma Intelligence, discusses key takeaways from a rece...